-
BIOTECanada will present the 2011 winners of the prestigious Gold Leaf Awards to companies and individuals in Canada’s biotech industry, whose demonstrated innovation and financial success in 2010 reflect the contribution biotech is making to the global bio-economy. Among the honourees were Cardiome Pharma Corp, Allon Therapeutics, EnWave Corporation and Sanofi-Pasteur.
-
Canada Pharma reports that the province of Ontario is helping GlaxoSmithKline expand its manufacturing facility in Mississauga. The move will result in new biotech jobs, creating up to 70 new jobs and protecting 300 existing jobs in the city. The company currently employs over 1,150 people in Ontario.
-
"The further expansion of the Prince Edward Island facilities of a major international bioscience company is evidence of the health of the bioscience sector in this province," says Innovation and Advanced Learning Minister Allan Campbell. Switzerland based Novartis has acquired a third building in Charlottetown to allow the company to strengthen its production and further augment its development activity on PEI.
-
A new seed fund, AmorChem, was recently announced by the Charest government. The $41.25-million fund's goal isn't to subsidize new companies, but rather to invest in scientific research, and then to reap the benefits when that research is sold off. The government hopes the investments will boost Quebec's sagging venture capital industry. AmorChem will follow a new model of funding for biotech ventures. The fund will finance about 40 projects over the next five years.
-
HTX announced an agreement to establish GE's first global Pathology Imaging Centre of Excellence in Toronto. GE Healthcare and its digital pathology joint venture, Omnyx, will invest $7.75 million. Planned collaborative research and development partnerships will bring an additional $7.2 million, for a total investment of $17.2 million over the next 3 years.
-
Genadyne Biotechnologies announced it will expand its services and products into the Canadian market. Headquartered out of Ontario, Genadyne Canada is bringing new products to the Canadian healthcare market. Genadyne Biotechnologies Inc. is a US based developer and manufacturer of negative pressure wound therapy systems, non-powered and powered pressure relieving therapeutic surfaces.
-
The National Research Council of Canada (NRC) and U.S. bioproducts company Metabolix announced that Metabolix is setting up operations at NRC's Industrial Partnership Facility in Saskatoon. Saskatoon is the geographic centre for numerous oilseed activities, offering extensive research facilities and supporting infrastructure. Richard Eno, President and CEO of Metabolix said that his company looks forward to the growth of the operations at NRC-PBI and, more broadly, across Canada.
-
It makes sense for growth-oriented companies to plant themselves where innovation thrives, where great minds have converged, and where the business climate encourages R&D. And it is said that Ontario is working hard to be that kind of place. Green energy, advanced manufacturing, life sciences and biotechnology, and information and communications technology all feed on Ontario's R&D. They thrive partly because of the province's talented work force and scientific community, and because of a tax structure that slashes companies' R&D costs. For specific example on how companies thrive in Ontario, please click on this headline.
-
Piramal Healthcare said it was planning acquisitions in the biotech space in the U.S., Europe and Canada in the next two to three years. Piramal recently sold its domestic drug business for $3.72 billion to U.S. pharmaceutical major Abbott Labs. "We want to collect a portfolio of small biotech companies abroad. One such acquisition was BioSyntech in Canada," Chairman Ajay Piramal said.
-
Ontario Premier Dalton McGuinty arrived in Tel Aviv on a trade mission to promote Ontario's life sciences industry to key partners and strengthen cultural ties with the Middle East. McGuinty will lead a business delegation of more than 40 people and meet key government and corporate partners in Jerusalem and Tel Aviv. During a visit to the West Bank, McGuinty will explore ways Ontario can help strengthen education, governance, small business creation and community development. And in Beirut, McGuinty will meet with key government and business leaders to discuss ways to leverage Ontario's 65,000-strong Lebanese-Canadian community to expand trade with Lebanon.
-
After attending the 2010 BIO International Convention, held in Chicago, from May 3 to 6, the Honourable Tony Clement, Minister of Industry, praised Canada's biotechnology industry as an important part of Canada's innovative economy. "Canada continues to rank among the global leaders in the life sciences," said Minister Clement. Minister Clement also talked about the government's strong commitment to innovation and the importance of their R&D investments in Canada.
-
Alberta's newly aligned research and innovation system, Alberta Innovates, is catching the attention of major multinational companies. Alberta has signed a memorandum of understanding with the Johnson & Johnson Corporate Office of Science and Technology (COSAT) to explore collaborative opportunities in health research and innovation. The MOU was signed at the BIO International Convention in Chicago, Illinois. The MOU is a commitment by Alberta and COSAT to assess opportunities for collaboration, funding, management and execution of projects for research and innovation in healthcare and life sciences, with the shared common goal of development and commercialization of technology.
-
Investissement Québec participera à BIO International Convention (BIO), qui se tient cette année à Chicago. Il s'agit de la plus grande conférence-exposition sur les biotechnologies du monde; 2 200 exposants de 60 pays seront présents, 20 000 visiteurs sont attendus et des centaines d'ateliers et de conférences figurent au programme. Le Québec offre de nombreux avantages aux entreprises des sciences de la vie dont la main-d'œuvre hautement qualifiée, les coûts d'exploitation très bas et des incitatifs fiscaux attrayants, particulièrement pour la recherche et le développement.
-
Investissement Québec will be at the upcoming BIO International Convention, held in Chicago. BIO is the world's largest biotechnology conference and exhibition, with 2,200 exhibitors from 60 countries, 20,000 expected visitors, and hundreds of workshops and talks scheduled. Québec offers many advantages to health science companies including highly skilled workers, very low operating costs and attractive tax incentives, particularly for research and development.
-
Atlantic Canada's biotech leaders are headed to Chicago, Illinois, to attend the largest annual gathering for their industry in the world. The Atlantic Canadian delegation, comprised of seven companies and four associations, will showcase their products and services at the Canadian pavilion. Other promotional opportunities include the convention's various networking receptions, one-on-one business development meetings, panel sessions and forums.
